Literature DB >> 8901067

Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.

C J Porter1, S A Charman, W N Charman.   

Abstract

Halofantrine hydrochloride is an important, highly lipophilic anti-malarial agent. A triple-cannulated anesthetized rat model was used to investigate the potential lymphatic transport of halofantrine (Hf). The effect of formulating Hf in vehicles representative of different physical (digestion) states of triglyceride lipid was also evaluated. The lipid vehicles were either a lipid solution, emulsion, or micellar system comprised of 50 microL of a 2:1 molar ratio of oleic acid:glycerol monooleate containing 2 mg of Hf free base. Lymph was collected from the mesenteric lymph duct, and blood was sampled from the jugular vein following intraduodenal infusion of the different formulations. Lymphatic transport was a major contributor to bioavailability as demonstrated by the recovery of up to approximately 20% of the administered dose in the intestinal lymph. The rank order effect of the vehicles for the promotion of lymphatic transport was micellar > emulsion > lipid solution. Lymphatic drug transport was predominantly associated with chylomicron-based transport. The extent of Hf absorption via the portal blood, estimated from the systemic plasma profiles in the lymph-cannulated rats, was largely independent of the administered formulations. These data indicate that lymphatic transport of the free base of Hf is a major contributor to oral bioavailability when formulated in appropriate lipid vehicles. The data suggest that formulation as increasingly disperse systems facilitates transport in this animal model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901067     DOI: 10.1021/js950221g

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  20 in total

1.  A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

Authors:  Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

2.  The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport.

Authors:  Natalie L Trevaskis; Luojuan Hu; Suzanne M Caliph; Sifei Han; Christopher J H Porter
Journal:  J Vis Exp       Date:  2015-03-06       Impact factor: 1.355

3.  Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Authors:  René Holm; Christopher J H Porter; Anette Müllertz; Henning G Kristensen; William N Charman
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

4.  The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS).

Authors:  Maria Høtoft Michaelsen; Kishor M Wasan; Olena Sivak; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2016-01       Impact factor: 4.009

5.  Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.

Authors:  R Holm; A Müllertz; G P Pedersen; H G Kristensen
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

6.  Bile increases intestinal lymphatic drug transport in the fasted rat.

Authors:  Natalie L Trevaskis; Christopher J H Porter; William N Charman
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

7.  Exploring the impact of drug properties on the extent of intestinal lymphatic transport - in vitro and in vivo studies.

Authors:  Emma Lawless; Brendan T Griffin; Aoife O'Mahony; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2014-11-27       Impact factor: 4.200

8.  Enhancement of oral moxidectin bioavailability in rabbits by lipid co-administration.

Authors:  Mohamad Firas Bassissi; Anne Lespine; Michel Alvinerie
Journal:  Parasitol Res       Date:  2004-08-26       Impact factor: 2.289

9.  Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats.

Authors:  Ditte M Karpf; René Holm; Henning G Kristensen; Anette Müllertz
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

10.  Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice.

Authors:  Vanessa C F Mosqueira; Philippe M Loiseau; Christian Bories; Philippe Legrand; Jean-Philippe Devissaguet; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.